Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2012; 01(01): 09-15
DOI: 10.4103/2278-330X.96494
Original Article

Importance of dose intensity in treatment of advanced nonsmall cell lung cancer in the elderly

Narayanan Prasad
Department of Medical Oncology, Kiran Majumdar Shah Cancer Center, Bangalore, Karnataka
,
Ashish Bakshi
Jupiter Hospital, Thane
,
Chetan Deshmukh
Deenanath Mangeshkar Hospital, Pune
,
Sachin Hingmire
Deenanath Mangeshkar Hospital, Pune
,
AA Ranade
Joshi Hospital, Pune
,
Purvish Parikh
Director of Clinical Research, BSES GH Hospital, Mumbai, Maharashtra, India
› Author Affiliations Source of Support: Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Maintaining appropriate dose intensity is important not only in the curative setting but also in treatment with palliative intent. We evaluated the outcome of advanced non small cell lung cancer treated with doublet platinum based chemotherapy. Outcome was compared between patients treated by medical oncologists at a tertiary cancer center and those treated by non medical oncologists in the community. The dose intensity, overall response rate and overall survival was significantly better when patients were treated by trained qualified and experienced medical oncologists. Hence, even in the palliative setting, cancer directed systemic therapy will yield maximum benefit for the patients when treated by medical oncologists.

Key words

chemotherapy - prolonged infusion - medical oncologist - response rate


Publication History

Article published online:
09 November 2020

© 2012. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cohen HJ. Oncology and aging. In: Hazzard WR, Blass JP, Ettinger WH, editors. Principles of Geriatric Medicine and Gerontology. 4 th ed. New York: McGraw-Hill; 1998.
  • 2 Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
  • 3 Vercelli M, Quaglia A, Casella C, Mangone L. Cancer patient survival in the elderly in Italy. Tumor 1997;83:490-6.
  • 4 Brown JS, Eraut D, Trask C, Davison AJ. Age and treatment of lung cancer. Thorax 1996;51:564-8.
  • 5 Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized clinical Trials. Br Med J 1995;311:899-909.
  • 6 Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Under representation of patients of 65 years of age or older in cancer treatment trials. N Engl J Med 1999;341:2061-7.
  • 7 Stinchcombe TE, Socinski MA. Drug development in patients with advanced non small cell lung cancer and poor performance status. Semin Oncol 2004;31 Suppl 11:S21-6.
  • 8 Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non small cell lung cancer: A phase II study. J Clin Oncol 1994;12:1535-40.
  • 9 Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine on patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 1996;32:243-8.
  • 10 Cattel L, Airoldi M, Delprino L. Pharmacokinetic evaluation of gemcitabine and 2′,2′-Difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 2006;17 Suppl 5:v142-7.
  • 11 Tibaldi C, Bernardini I, Chella A. Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. Lung Cancer 2006;51:217-23.
  • 12 Xu N, Shen P, Zhang XC, Yu LF, Bao HY, Shi GM, et al. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2007;59:1-7.
  • 13 Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129-34.
  • 14 Parikh PM, Narayanan P, Mistry RC, Agarwal JP, Pai VR, Nair R, et al. Treatment of advanced NSCLC with low dose gemcitabine and carboplatin. ASCO Abstract Book; 2005.
  • 15 Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2004;46:61-76.
  • 16 Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. A prognostic model for advanced stage nonsmall cell lung cancer: Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-92.
  • 17 Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
  • 18 Hespanhol V, Queiroga H, Magalhaes A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995;13:253-67.